Karyopharm Details SENTRY Myelofibrosis Trial Results, Hosts Endometrial Cancer Webcast
KPTI•Karyopharm will host a virtual fireside chat on June 8 at 12:00 p.m. ET featuring Dr. Robert Coleman, PI of the Phase 3 XPORT-EC-042 endometrial cancer trial. The company also released a transcript detailing Phase III SENTRY trial results evaluating selinexor plus ruxolitinib in myelofibrosis, potentially impacting its hematologic pipeline.
1. Upcoming Endometrial Cancer Webcast
Karyopharm will participate in a virtual fireside chat on June 8 at 12:00 p.m. ET, featuring senior management and Dr. Robert Coleman, PI of the Phase 3 XPORT-EC-042 trial in TP53 wild-type endometrial cancer. Institutional investors can join live via Cantor, with a replay available at 2:00 p.m. ET on the company’s Investors & Media website.
2. Phase III SENTRY Trial Transcript Release
The company released a transcript of its discussion on the Phase III SENTRY trial, which evaluated selinexor plus ruxolitinib in patients with myelofibrosis. Details include efficacy and safety findings that could inform next steps in the hematologic oncology pipeline and influence future commercial prospects.
